Navigation Links
Study reveals H1N1 unexpected weakness
Date:12/10/2009

The H1N1 influenza virus has been keeping a secret that may be the key to defeating it and other flu viruses as well.

Researchers at Rice University and Baylor College of Medicine (BCM) have found what they believe is a weakness in H1N1's method for evading detection by the immune system.

Comparing its genetic sequences going all the way back to the virus's first known appearance in the deadly "Spanish flu" outbreak of 1918, they discovered a previously unrealized role of receptor-binding residues in host evasion, which effectively becomes a bottleneck that keeps the virus in check.

Rice's Jianpeng Ma and graduate student Jun Shen and BCM's Qinghua Wang compared the sequences of more than 300 strains of H1N1 to track its evolution; they reported their results in a recent online edition of the scientific journal PLoS ONE.

The researchers were looking in particular at hemagglutinin (HA), the protein "hook" that allows the virus to attach itself to and infect host cells. It's long been known that five regions of H1N1's HA serve as antigenic sites, the protein fragments that trigger the body's immune system. These antigenic sites, first mapped in 1981, shuffle their amino-acid sequences in the endless cat-and-mouse game that viruses play to survive.

The researchers discovered several key residues involved in both antigenic sites and the receptor-binding site, the part of the protein that attaches to a cell and allows the virus to invade.

The common belief has been that the receptor binding could not change. "The site is known, but no one thought it was involved in the immune system. In order to recognize the receptor, that particular region has to be robust," Ma said. "But it turns out this region is not only variable, but also interacts with the immune system."

For a virus to evade antibodies, all five antigenic sites would have to disguise themselves by mutating. The new finding led the researchers to believe the receptor-binding residues would also have to mutate, but not so much that the binding no longer works. "If the binding is abolished, the virus dies," said Ma, a Rice professor in bioengineering with a joint appointment at BCM.

Such dual-function residues are a likely bottleneck for the virus, he said, because they're under the tightest restrictions. Thus, they could be easier to track over time and may chart a path to predict future mutations that will aid in vaccine design.

"It becomes a weak link and provides us with a window into the virus that we can monitor," Ma said. "The virus's bottleneck is our opportunity."

Wang, an assistant professor of biochemistry and molecular biology at BCM who has long studied the structure and function of HA, has been involved in the project since it began and is now working to verify the results in vitro. She hopes confirming the computations will lead to more efficiency in creating vaccines not only for H1N1 but also for other strains of the flu.

"An underlying implication is that this may not be restricted to H1N1," Wang said. "It may apply to other influenza viruses as well. If studying viral evolution can help predict what will cause a severe problem in humans, you can actually pre-stock vaccines, which will save time."


'/>"/>

Contact: David Ruth
druth@rice.edu
713-348-6327
Rice University
Source:Eurekalert  

Related biology news :

1. Tropical birds waited for land crossing between North and South America: UBC study
2. Studying hair of ancient Peruvians answers questions about stress
3. Study confirms association between tobacco smoke and behavioral problems in children
4. Study reveals how Arctic food webs affect mercury in polar bears
5. Study finds new relationship between gene duplication and alternative splicing in plants
6. Spices halt growth of breast stem cells, U-M study finds
7. Study shows nearly 1/3 of human genome is involved in gingivitis
8. U-Iowa study helps advance heart-related research
9. Study finds logging effects vary based on a forests history, climate
10. Study shows pine bark improves circulation, swelling and visual acuity in early diabetic retinopathy
11. Clemson researchers receive EPA grant to study carbon emission storage
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study reveals H1N1 unexpected weakness
(Date:6/22/2016)... 2016 On Monday, the Department of Homeland ... share solutions for the Biometric Exit Program. The Request ... Protection (CBP), explains that CBP intends to add biometrics ... the United States , in order to deter ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/9/2016)... 9, 2016  Perkotek an innovation leader in attendance control systems is proud to ... hours, for employers to make sure the right employees are actually signing in, and ... ... ... ...
(Date:6/2/2016)... The Weather Company , an IBM Business (NYSE: IBM ... which consumers will be able to interact with IBM Watson ... or text and receive relevant information about the product or ... long sought an advertising solution that can create a one-to-one ... valuable; and can scale across millions of interactions and touchpoints. ...
Breaking Biology News(10 mins):
(Date:12/4/2016)... ... December 03, 2016 , ... ... A microbiome impact grant award has been made to Dr. Renato Polimanti of ... and drinking on the oral microbiome. Grant proposals have been vetted by the ...
(Date:12/2/2016)... ... 02, 2016 , ... In anticipation of AxioMed’s exclusive cleanroom ... company President, Jake Lubinski will be traveling to Switzerland from December 5-10. Mr. ... Lucerne, and Zurich to discuss the benefits of a viscoelastic disc. AxioMed received ...
(Date:12/2/2016)... Dec. 2, 2016 Amgen (NASDAQ: AMGN ... announced the submission of a Marketing Authorization Application (MAA) to ... candidate to Avastin ® (bevacizumab). The companies believe this ... EMA. "The submission of ABP 215 to ... expand our oncology portfolio," said Sean E. Harper , ...
(Date:12/2/2016)... ... December 01, 2016 , ... ACEA Biosciences, Inc. announced today that it will ... AC0010 at the World Conference on Lung Cancer 2016, taking place in Vienna, Austria ... I/II clinical trials for AC0010 in patients with advanced non-small cell lung cancer harboring ...
Breaking Biology Technology: